About ZYTIGA® (abiraterone acetate)

What is ZYTIGA®

ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Since its approval in 2011, more than 100,000 men in the U.S. have been prescribed ZYTIGA®.1

Estimate based on sales and use data from April 2011 to December 2016.

About Zytiga

Efficacy of Zytiga

Efficacy of ZYTIGA®

Significant results and an established safety profile.

Accessing ZVT

Accessing ZYTIGA®

Identifying the cost support options available to your patients.


ZYTIGA® + Prednisone

Understanding the role of prednisone in treatment.


The Janssen Commitment